In early November, Farmak JSC, a leader of domestic pharmaceutical industry, held Farmak MRT School 2014, a two-day Scientific and Practical Conference for Radiologists. This is the third event in this format organized by Farmak JSC.
One hundred and forty radiologists from all regions of Ukraine participated in the Conference where the best Ukrainian experts in Magnetic Resonance Imaging (MRI) delivered their presentations. The MRI capabilities in diagnosis of cardiovascular diseases in adults and children were discussed at the Conference. The focus was on normal anatomy and congenial malformations, diagnosis of myocarditis. The Conference considered the specific aspects of MRI use in neuroradiology and musculoskeletal radiology in children, prenatal and postnatal diagnosis of brain anomalies.
In addition to theoretical part, 13 experts presented their practical cases within the framework of Farmak MRT School 2014.
Valeriy Yuschuk, Marketing Advisor, Farmak JSC, says, “Today, Farmak is the only company, which directs its activities for development of the specialists engaged in magnetic resonance imaging area. Besides the lectures, we also provide practical modules, where the speakers demonstrate nontrivial clinical cases from their own practical experience, within the framework of Farmak MRT School 2014. Every case is discussed in detail by the participants of the School, which makes it possible to improve the practical skills.
Volodymyr Rogozhyn, President of Ukrainian Association of Radiologists, M.D., Director of Radiology Center at Borys Clinic, Medical Radiology Department, National Medical Academy of Postgraduate Education, says, “The problem of radiologists’ education has always been topical. Unlike the other companies, which close up their educational programs, Farmak continues to work in this direction. That is extremely significant”.
We should remind that this is the third MRI School organized by Farmak so far. The first two scientific and practical conferences were held in 2010 and 2012.
The pharmaceutical company JSC “Farmak” considers the possibility of launching the manufacture of products, in particular, diagnostic test kits, to combat coronavirus spread. “Now we analyse the possibility of arranging the release of supportive care products, disinfectants and antiseptics, diagnostic test kits, protective medical products, including masks, ...
Farmak reinvests 95% of its profits in the development. “We have never paid more than 5% of our profits as dividends. We have reinvested everything in the development. Due to this, Farmak’s capitalization can be estimated at $850 million to $1 billion today. If I sell the shares that I hold, I will earn a […]
The Memorandum is aimed at developing the mutual cooperation in the implementation of the state programs of the Republic of Uzbekistan for the further development of the national pharmaceutical industry. “We know the Uzbek market well and we are committed to develop cooperation. Farmak has been present in Uzbekistan since 2004. The residents of this [&hellip...